Beckman Coulter Life Sciences

Cepheid is a leading American molecular diagnostics company dedicated to improving healthcare by developing, manufacturing, and marketing innovative and easy-to-use molecular systems and tests. A subsidiary of Danaher Corporation since 2016, Cepheid has been at the forefront of automating complex and time-consuming manual laboratory procedures, making sophisticated genetic testing more accessible to institutions of all sizes. The company's mission is to enable medical providers to identify and treat diseases early, thereby increasing the opportunities to improve patient survival and quality of life. By focusing on applications where rapid, accurate, and actionable test results are most critical, such as in the management of infectious diseases and cancer, Cepheid's solutions empower healthcare professionals to make timely and informed decisions.

Founded in 1996, Cepheid revolutionized the field of molecular diagnostics with its flagship product, the GeneXpert® system. This platform automates sample preparation, DNA amplification, and detection, delivering 'sample-to-answer' results in a self-contained, single-use cartridge. This technology has been pivotal in various global health crises, providing rapid testing for diseases like tuberculosis, HIV, hepatitis, and most notably, COVID-19. The GeneXpert system's scalability and ease of use have enabled its deployment in diverse settings, from centralized high-throughput laboratories to near-patient and point-of-care locations, including in low- and middle-income countries through its Global Access program. Headquartered in Sunnyvale, California, Cepheid continues to expand its extensive portfolio of tests and systems, driving innovation in diagnostics to address the world's most complex health challenges and improve patient outcomes globally.